Evidence map›Paper›PMID 41113720›Full record

ArticleFrontiers in endocrinology2025

Yuanfang Zhang, Yingqiu Wang, Donghua Sun, Chao Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuanfang Zhang *Department of Nuclear Medicine and Neurology, Tenth People's Hospital of Tongji University, Shanghai, China.
Yingqiu Wang *Department of Nuclear Medicine, Yangpu Hospital of Tongji University, Shanghai, China.
Donghua Sun *Department of Nuclear Medicine and Neurology, Tenth People's Hospital of Tongji University, Shanghai, China.
Chao MaDepartment of Nuclear Medicine and Neurology, Tenth People's Hospital of Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The main determinant of skeletal fragility in postmenopausal patients with differentiated thyroid cancer (DTC) and osteopenia is thyroid-stimulating hormone (TSH) suppressive therapy. Evidence for the use of bisphosphonates, including technetium-99 methylene diphosphonate ( Objective: To investigate the effects of Methods: A total of 102 postmenopausal patients with DTC and osteopenia under TSH suppression therapy were enrolled in this open-label, prospective study. Patients were divided into two groups: calcium/vitamin D supplements (group Results: The combined Conclusions: Trial registration number: ChiCTR2200064170.

Indexed as

Bone DensityBone Density Conservation AgentsBone Diseases, MetabolicPostmenopauseTechnetium Tc 99m MedronateThyroid NeoplasmsThyrotropinAgedCalciumFemaleHumansMiddle AgedProspective StudiesVitamin DBone Density Conservation AgentsCalciumTechnetium Tc 99m MedronateThyrotropinVitamin D99Tc-MDPbone mineral densitydifferentiated thyroid cancerosteopeniathyroid stimulating hormone suppression

Identifiers

PMID41113720
PMCPMC12527890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.